Tadeusz Hawrot

European Parliament

2 papers in the library · 25 citations · publishing 2025

Papers

Implementing psychedelic-assisted therapy: History and characteristics of the Swiss limited medical use program

Neuroscience Applied January 1, 2025 Matthias E. Liechti, Peter Gasser, Helena Aicher et al. 16 citations

Switzerland's limited access program for psychedelic/MDMA-assisted therapy, started in 2014 with two physicians, had grown to about 100 physicians by 2024, treating 723 patients (245 with MDMA, 130 with LSD, 348 with psilocybin). Approximately 1660 treatments occurred in 2024, with patients typically receiving 2-4 sessions within 12 months. The program is authorized by the Swiss Federal Office of Public Health for patients with mostly incurable diseases where the substance can alleviate suffering and no alternatives exist or have failed. The article describes the program's history, legal requirements, costs, professional roles, education, patient characteristics, outcomes, and adverse effects, comparing it to similar programs in Canada and Australia.

DOI: 10.1016/j.nsa.2025.105525 Psychology Medicine

A lexicon for psychedelic research and treatment

Drug Science Policy and Law September 1, 2025 David Nutt, David Erritzøe, Anne Katrin Schlag et al. 9 citations

The field of psychedelic research lacks standardized terminology for clinical development, dosing, safety monitoring, and regulatory classification. A comprehensive framework is proposed that classifies psychedelics by pharmacology (serotonergic, glutamatergic, kappaergic, GABAergic, and atypical), introduces dose-dependent categories (microdose, minidose, mididose, macrodose), and standardizes terms like “short-acting” with specific pharmacokinetic parameters. Safety considerations include cardiovascular and psychological effects, with risk mitigation protocols for higher-risk compounds like ibogaine. A three-phase treatment model—preparation, dosing, and integration—is recommended as a minimum standard. The lack of comparative research on psychotherapy modalities is identified as a critical gap.

DOI: 10.1177/20503245251380511